CCR5 Antagonist RAP-103 Protects Synapses in Dementia
Synapse loss is the principal cause of cognitive decline in Alzheimer's disease (AD) and related disorders ( LBD, ADRD). Many,… Continue Reading
RAP-103 Inhibits Opioid-derived Dependence, Withdrawal and Respiratory Depression
Creative Bio-Peptides, Inc, a preclinical-stage biotechnology company developing novel therapies to balance the innate immune system and promote regeneration of… Continue Reading
RAP-103 Benefits in Pain Published
Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Provide Opioid Sparing Post-Surgical Pain Relief and Treatment… Continue Reading
NIH SBIR AWARD FOR SYNAPSE PROTECTING TREATMENTS FOR ALZHEIMER’S DISEASE
Creative Bio-Peptides, Inc has been funded by the National Institute on Aging (NIA) as part of NIH’s strategic plan to… Continue Reading
CREATIVE BIO-PEPTIDES RECEIVES NIH HEAL AWARD FOR OPIOID ABUSE DISORDERS
Creative Bio-Peptides, Inc has been funded as part of the NIH’s HEAL Initiative on building technologies to stop the opioid… Continue Reading
CREATIVE BIO-PEPTIDES and LEIDOS AWARDED US DOD CONTRACT
RAP-103 is the new oral analog of Peptide T ( Dala1-peptide T-amide, aka"DAPTA") which was discovered as an anti-viral for… Continue Reading
